Company Description
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States.
The company’s product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels.
It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019.
Verve Therapeutics, Inc. was incorporated in 2018 and is based in Boston, Massachusetts. As of July 25, 2025, Verve Therapeutics, Inc. operates as a subsidiary of Ridgeway Acquisition Corporation.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jun 17, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 274 |
| CEO | Sekar Kathiresan |
Contact Details
Address: 201 Brookline Avenue, Suite 601 Boston, Massachusetts 02215 United States | |
| Phone | 617 603 0070 |
| Website | vervetx.com |
Stock Details
| Ticker Symbol | VERV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001840574 |
| CUSIP Number | 92539P101 |
| ISIN Number | US92539P1012 |
| Employer ID | 82-4800132 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sekar Kathiresan M.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. Burt A. Adelman M.D. | Co-Founder and Independent Chairman of the Board |
| Andrew D. Ashe J.D. | President, Chief Operating Officer and General Counsel |
| Allison Dorval CPA | Chief Financial Officer and Principal Accounting Officer |
| Dr. Kiran Musunuru M.D., M.P.H., Ph.D. | Co-Founder |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Dr. Anthony Philippakis M.D., Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Co-Founder |
| Issi Rozen M.B.A. | Co-Founder and Strategic Advisor |
| Dr. Troy Lister Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 28, 2025 | SCHEDULE 13G/A | Filing |
| Jul 25, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jul 25, 2025 | 8-K | Current Report |
| Jul 25, 2025 | POSASR | Filing |
| Jul 25, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 25, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 25, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 25, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 25, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jul 25, 2025 | 25-NSE | Filing |